iBio, Inc. Form 10-Q Summary
Business Context and Reporting Period
iBio, Inc. is transitioning from a contract development and manufacturing organization (CDMO) to an AI-driven precision antibody discovery and development company. The filing covers the fiscal quarter and six months ended December 31, 2022, filed February 14, 2023. The CDMO operations are presented as discontinued operations and assets held for sale.
The continuing business includes the IBIO-101, EGFRvIII, CCR8, MUC16 and PD-1 agonist programs, additional early-stage discovery programs, and the AI drug-discovery platform acquired from RubrYc Therapeutics. The company paused IBIO-101 IND-enabling studies pending competing clinical data and expects the IND filing to move from the first half of 2024 to the first half of 2025.
Key Financial Metrics
| Metric | Three months ended Dec. 31, 2022 | Six months ended Dec. 31, 2022 |
|---|---|---|
| Continuing-operations revenue | $0 | $0 |
| Continuing-operations operating expenses | $10.6 million | $18.2 million |
| Loss from continuing operations | $10.6 million | $18.1 million |
| Loss from discontinued operations | $23.0 million | $33.6 million |
| Net loss attributable to iBio stockholders | $33.6 million | $51.7 million |
| Total loss per share | $3.42 | $5.54 |
| Net cash used in operating activities | Not separately provided | $21.6 million |
- Discontinued CDMO revenue was $130,000 in the quarter and $186,000 for the six-month period. Continuing-operations revenue was nil.
- Cash and cash equivalents were $3.7 million at December 31, 2022. Restricted cash was $253,000 and debt-security investments were $5.9 million, for combined cash, restricted cash and debt securities of approximately $9.9 million.
- Total assets were $51.8 million, compared with $99.4 million at June 30, 2022. Stockholders’ equity was $18.8 million, compared with $63.5 million.
- The term note payable was $16.0 million net of deferred financing costs. Equipment financing totaled approximately $475,000, and lease obligations totaled approximately $4.4 million.
- The accumulated deficit was $275.6 million at December 31, 2022.
Material Changes Versus the Prior Comparable Period
- Quarterly net loss increased to $33.6 million from $11.9 million, primarily because of the CDMO wind-down and asset impairment charges.
- Six-month net loss increased to $51.7 million from $20.9 million. Six-month operating cash use increased to $21.6 million from $20.0 million.
- Continuing-operations research and development expense increased to $2.8 million from $1.9 million for the quarter and to $5.3 million from $3.0 million for six months.
- Continuing-operations general and administrative expense increased to $7.8 million from $5.4 million for the quarter and to $12.9 million from $9.5 million for six months. The quarterly increase included approximately $2.13 million of former CEO separation-related expense.
- The company recorded approximately $17.6 million of CDMO fixed-asset impairment charges and $4.9 million of inventory reserves during the six months. CDMO-related personnel and severance costs were approximately $5.8 million.
- The company reduced its workforce by approximately 60%, or 69 positions, and ceased CDMO operations. Management expects the transition to reduce annual spending by approximately 50% and monthly burn to approximately $2.5 million to $3.0 million.
- The company completed a $1.2 million net at-the-market equity issuance and a December public offering that generated approximately $2.9 million of net proceeds. The offering also issued substantial warrants, creating potential future dilution.
- Shares outstanding increased from 8.7 million at June 30, 2022 to 12.4 million at December 31, 2022, excluding the potential effect of outstanding warrants and other equity awards.
Guidance, Outlook, Risks and Unusual Items
- Management stated that approximately $9.9 million of cash, restricted cash and debt securities was not expected to fund operations through the third quarter of fiscal 2023 without additional cost reductions, asset sales or financing.
- The financial statements include substantial doubt regarding the company’s ability to continue as a going concern. Management expects to require additional capital to execute its longer-term plan and had no committed source of such funding.
- The company is pursuing the sale of the CDMO facility and related equipment. The assets held for sale included approximately $20.5 million of current assets at December 31, 2022, primarily property and equipment. There is no assurance regarding the timing or proceeds of a sale.
- The Woodforest credit agreement required a $7.5 million unrestricted cash balance, subject to a possible reduction to $5.0 million upon satisfaction of a specified milestone. The company fell below the covenant in January 2023, creating a default that was waived under a February 9, 2023 amendment. Failure to satisfy the amendment’s milestone could permit acceleration of the debt and action against collateral.
- The company is required to pay Woodforest $5.1 million within two business days after receiving the corresponding Fraunhofer settlement payment, in addition to scheduled principal amortization of $250,000 per month through March 2023.
- Management terminated the IBIO-100 anti-fibrotic program and notified the University of Pittsburgh in February 2023 that it was terminating the related license. The related intangible asset was fully impaired by $25,000.
- The company’s former CEO resigned effective December 1, 2022. The company later appointed an interim CEO and interim CFO after the reporting date.
- The approximately $5.0 million IBIO-101 indefinite-lived intangible asset was not impaired at December 31, 2022 but was identified as at risk. Management disclosed that changes in discount rates, approval probabilities, stock price or development plans could produce future material impairment charges.
- The company has a CRO commitment of approximately $697,000 in additional costs for IBIO-101 development as of the filing date.
Most Important Facts for Investors to Verify
- Whether the company can obtain additional financing or complete a CDMO asset sale before available liquidity is exhausted.
- Whether the Woodforest liquidity-covenant waiver remains effective and whether the required milestone is achieved without triggering debt acceleration.
- The timing, amount and collectability of the remaining Fraunhofer settlement and license receivables, including the $5.1 million amount pledged to Woodforest.
- The actual sale value and timing for the Bryan, Texas facility and related equipment compared with the carrying value and secured debt.
- The potential dilution from approximately 8.0 million warrants issued or outstanding in connection with the December offering, in addition to options and restricted stock units.
- Whether the IBIO-101 development delay, program prioritization and AI platform acquisition produce meaningful clinical or partnership milestones.
- Future impairment risk for the IBIO-101 intangible asset and other acquired intellectual property.